Executive Team

Ethan Shen, Ph.D., Chief Executive Officer and Chairman, has served as Chief Executive Officer and Chairman of the Board since March 2024. Dr. Shen has served as Chief Executive Officer and founder of Yong Ding Biopharma Co., Ltd., the subsidiary of YD Biopharma since 2013. Dr. Shen has deep expertise in translational medicine, new drug development, medical-grade health product development, and financial management. From 2001 to 2008 Dr. Shen served as the Key Account Manager at Novartis, where he managed projects and oversaw new drug submissions. His expertise spans R&D, innovation and entrepreneurship, financial management, as well as genetics and cellular technologies. Dr. Shen is currently director of EG BioMed and Shen Capital Co., Ltd. Dr. Shen graduated from Taipei Medical University with a degree in Pharmacy and holds a pharmacist license. Dr. Shen also holds a master’s degree in finance from Baruch College, CUNY, and executive MBA degrees from National Taiwan University and Fudan University. Dr. Shen obtained a Ph.D. in Translational Medicine from Academia Sinica and Taipei Medical University.

Edmund Hen, Chief Financial Officer, has served as Chief Financial Officer since December 2024. From August 2008 to November 2024, Mr. Hen served as Chief Financial Officer at Antelope Enterprise Holdings Ltd. (Nasdaq: AEHL), where he led the corporate finance team and was responsible for overseeing the company’s initial public offering, SEC compliance and reporting, and financial forecasting. From November 2006 to August 2008, Mr. Hen served as Chief Financial Officer of Sichuan Guanglin Electric Co., Ltd., a switchgear manufacturer, where he was responsible for the company’s pre-IPO fundraising and overall financial strategy. Mr. Hen also served as Chief Financial Officer of Guanhong (China) Limited, a leading cloth dyeing processing manufacturer in Fujian China from July 2005 to October 2006, and Accounting Manager of Dickson Concepts (International) Limited, Hong Kong (HKEX: 113), a luxury brand retailer in Hong Kong and China. Mr. Hen also worked at a variety of international accounting firms in assurance and advisory services during the period from 1995 to 2001. Mr. Hen is a senior member of the Institute of Chartered Accountants in England and Wales, and a member of the Hong Kong Institute of Certified Public Accountants. Mr. Hen graduated from the University of East Anglia, UK, with a Bachelor of Science in Accounting and Finance. Mr. Hen also holds a Master of Science in Professional Accounting from the University College London, UK.

Benjamin Zhang, M.D., Chief Medical Officer and Director, has served as Chief Medical Officer and Director since January 2025. Dr. Zhang has served as Chief Medical Officer at JY BioMedical since 2024, and as a resident doctor at Taipei Medical University Hospital since 2023. Dr. Zhang is a dedicated medical professional with extensive expertise in immune cell research, stem cell therapy, cell engineering, and clinical trial management. Dr. Zhang is a leader in cancer immunotherapy, regenerative medicine, and translational medicine. His innovative contributions include the development of proprietary protocols for gamma delta T cell expansion, mesenchymal stem cell (MSC) treatments for glioblastoma, hepatocellular carcinoma, Parkinson’s disease, and lung cancer, and exosome-based therapeutics. Additionally, Dr. Zhang has secured multiple U.S. FDA Drug Master File (DMF) qualifications for cutting-edge cell and exosome therapies. From 2023 to 2024, Dr. Zhang served as a Cell Engineer at SL-Link Co., Ltd., where he focused on optimizing cell culture processes and enhancing biomanufacturing efficiency. From 2019 to 2021, Dr. Zhang served as a part-time research assistant at Taipei Medical University, where he designed and implemented translational research experiments, focusing on unmet medical needs. Dr. Zhang holds a certification in Cell Therapy Techniques and is a certified Cell Therapy R&D Engineer. Dr. Zhang graduated from the School of Medicine at Taipei Medical University with a Doctor of Medicine degree. We believe Dr. Zhang is qualified to serve on our board of directors due to his expertise in cancer immunotherapy and regenerative medicine.